Scholarlink

<p>Cisplatin-based chemotherapy is the primary treatment for advanced bladder cancer; however, numerous patients experience treatment failure because of chemoresistance. Therefore, it is crucial to identify drivers of chemoresistance and determine strategies to counteract them to improve prognosis in bladder cancer patients. This study performed proteomics analysis of clinical samples of cisplatin-naïve and resistant bladder cancer tissues. Furthermore, the GEO and TCGA datasets were integrated, which revealed latent transforming growth factor β binding protein 1 (LTBP1) as a potential gene associated with chemoresistance in bladder cancer. LTBP1 expression was correlated with clinical stage and patient survival. LTBP1 knockdown in bladder cancer cells inhibited proliferation, migration, invasion, and chemoresistance <i>via</i> TGF-β-mediated epithelial-mesenchymal transition. Subcutaneous tumor and lung metastasis mouse models revealed that LTBP1 inhibition combined with cisplatin treatment significantly inhibited tumor growth and metastasis. Higher LTBP1 expression is associated with a worse prognosis and advanced stage in bladder cancer patients. In conclusion, this study revealed that LTBP1 may be a potential target for alleviating chemoresistance in bladder cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Zongyang Li,
  • Yongbo Yu,
  • Fang Liu,
  • Yushu Wu,
  • Yunjiang Zang,
  • Yanhong Ding,
  • Zhilei Zhang

摘要

Cisplatin-based chemotherapy is the primary treatment for advanced bladder cancer; however, numerous patients experience treatment failure because of chemoresistance. Therefore, it is crucial to identify drivers of chemoresistance and determine strategies to counteract them to improve prognosis in bladder cancer patients. This study performed proteomics analysis of clinical samples of cisplatin-naïve and resistant bladder cancer tissues. Furthermore, the GEO and TCGA datasets were integrated, which revealed latent transforming growth factor β binding protein 1 (LTBP1) as a potential gene associated with chemoresistance in bladder cancer. LTBP1 expression was correlated with clinical stage and patient survival. LTBP1 knockdown in bladder cancer cells inhibited proliferation, migration, invasion, and chemoresistance via TGF-β-mediated epithelial-mesenchymal transition. Subcutaneous tumor and lung metastasis mouse models revealed that LTBP1 inhibition combined with cisplatin treatment significantly inhibited tumor growth and metastasis. Higher LTBP1 expression is associated with a worse prognosis and advanced stage in bladder cancer patients. In conclusion, this study revealed that LTBP1 may be a potential target for alleviating chemoresistance in bladder cancer.